{
    "nct_id": "NCT05238883",
    "official_title": "A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Previously received the following lines of systemic therapy for the advanced/metastatic disease:\n\n  * Gastric cancer: at least 2 lines of therapy\n  * Renal cell carcinoma: at least 2 lines of therapy\n  * Melanoma:\n\n    * BRAF V600E mutant: must have received at least 2 lines of therapy\n    * BRAF V600E wild type: must have received at least 1 line of therapy\n  * Sarcoma: at least 1 line of therapy\n  * Testicular germ cell tumor: at least 2 lines of therapy\n  * Cervical cancer: at least 2 lines of therapy\n  * Mesothelioma: at least 2 lines of therapy\n  * Non-small cell lung cancer: at least 2 lines of therapy\n  * Head and neck squamous cell carcinoma: at least 2 lines of therapy\n* Suitable site to biopsy at pre-treatment and on-treatment\n* Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or modified RECIST (mRECIST) for mesothelioma\n* Eastern Cooperative Oncology Group performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Systemic anti-cancer therapy within 2 weeks prior to start of study drug or within 4 weeks for immune-oncologic therapy\n* For soft tissue sarcoma and testicular germ cell tumor patients only: prior immune therapy\n* Therapeutic radiation therapy within the past 2 weeks\n* Prior exposure to agents targeting the Tumor Necrosis Factor Receptor type 2 (TNFR2) receptor\n* Active autoimmune disease requiring systemic treatment in the previous 2 years\n* Systemic steroid therapy (>10 mg/day of prednisone or equivalent) or any immune suppressive therapy ≤ 14 days before first dose\n* Persisting toxicity of ≥Grade 2 (≥Grade 1 for diarrhea) relating to prior anti cancer therapy with the following exceptions:\n\n  * All grades of alopecia are acceptable\n  * Endocrine dysfunction on replacement therapy is acceptable\n* Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition\n* Major surgery within 4 weeks of the first dose of study drug\n* History or presence of drug or non-drug induced interstitial lung disease or pneumonitis ≥Grade 2. For combination only: non-small cell lung cancer patients, mesothelioma or patients with significantly impaired pulmonary function or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening\n* History of allergic reactions, immune related reactions, or cytokine release syndrome (CRS) attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any excipient of HFB200301\n* Using sensitive substrates of major cytochrome P450 (CYP450) enzymes\n* Known active malignancy, with the exception of the specific cancer under investigation in this trial, that required treatment within the previous 2 years\n* For combination only:\n\n  * Prior randomization in a tislelizumab study regardless of the treatment arm, until the primary and key secondary endpoints of the study have read out\n  * Hypersensitivity to tislelizumab or any of its excipients.",
    "miscellaneous_criteria": ""
}